Stock ZIMLAB ZIM LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials ZIM Laboratories Limited

Equities

ZIMLAB

INE518E01015

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:49 2024-05-28 am EDT 		5-day change 1st Jan Change
104.3 INR +0.34% Intraday chart for ZIM Laboratories Limited -6.50% -9.50%
May. 14 Zim Laboratories' Consolidated Profit Climbs in Fiscal Q4; Shares Slide 5% MT
May. 13 ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023
Capitalization 1 2,018 905.3 1,178 2,596 3,528
Enterprise Value (EV) 1 2,788 1,810 1,987 3,095 4,085
P/E ratio 13.2 x 27.6 x 16.1 x 17.8 x 14.5 x
Yield 0.4% - - - -
Capitalization / Revenue 0.6 x 0.33 x 0.38 x 0.78 x 0.89 x
EV / Revenue 0.83 x 0.65 x 0.65 x 0.93 x 1.02 x
EV / EBITDA 6.62 x 7.68 x 5.22 x 7.98 x 8.19 x
EV / FCF 64.3 x -14.9 x 18.5 x 12.8 x -29.3 x
FCF Yield 1.56% -6.71% 5.41% 7.81% -3.41%
Price to Book 1.34 x 0.59 x 0.73 x 1.48 x 1.76 x
Nbr of stocks (in thousands) 48,359 48,542 48,726 48,726 48,726
Reference price 2 41.73 18.65 24.17 53.28 72.40
Announcement Date 9/7/19 9/8/20 9/8/21 8/26/22 6/16/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 2,729 3,354 2,778 3,073 3,335 3,986
EBITDA 1 345 421.1 235.6 381 387.9 499
EBIT 1 251.8 310.9 102 240.6 250.3 352.6
Operating Margin 9.23% 9.27% 3.67% 7.83% 7.51% 8.85%
Earnings before Tax (EBT) 1 249.4 220.7 0.686 102.3 210.4 353.6
Net income 1 191.1 153.4 32.97 73.18 145.5 244.3
Net margin 7% 4.57% 1.19% 2.38% 4.36% 6.13%
EPS 2 3.928 3.150 0.6767 1.500 2.986 5.010
Free Cash Flow 1 -93.08 43.36 -121.5 107.5 241.8 -139.3
FCF margin -3.41% 1.29% -4.37% 3.5% 7.25% -3.49%
FCF Conversion (EBITDA) - 10.3% - 28.22% 62.34% -
FCF Conversion (Net income) - 28.26% - 146.93% 166.2% -
Dividend per Share 2 0.1667 0.1667 - - - -
Announcement Date 6/24/18 9/7/19 9/8/20 9/8/21 8/26/22 6/16/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 818 770 905 810 499 557
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.371 x 1.827 x 3.841 x 2.125 x 1.286 x 1.117 x
Free Cash Flow 1 -93.1 43.4 -121 108 242 -139
ROE (net income / shareholders' equity) 15% 10.7% 2.16% 4.65% 8.65% 13%
ROA (Net income/ Total Assets) 5.65% 6.2% 1.95% 4.63% 4.7% 6.45%
Assets 1 3,384 2,474 1,690 1,582 3,099 3,788
Book Value Per Share 2 28.20 31.20 31.70 33.00 36.10 41.10
Cash Flow per Share 2 0.3000 0.1000 0.3000 0.2900 0.7000 1.320
Capex 1 285 204 185 64.8 152 367
Capex / Sales 10.45% 6.07% 6.67% 2.11% 4.57% 9.2%
Announcement Date 6/24/18 9/7/19 9/8/20 9/8/21 8/26/22 6/16/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
ZIM LABORATORIES LIMITED Stock ZIM Laboratories Limited
-9.50% 60.93M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+16.31% 42.32B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+15.43% 21.29B
SANDOZ GROUP AG Stock Sandoz Group AG
+19.33% 15.29B
CIPLA LIMITED Stock Cipla Limited
+18.71% 14.36B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+52.78% 12.81B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-12.58% 6.58B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.28% 5.51B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ZIMLAB Stock
  4. Financials ZIM Laboratories Limited